β-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: Part 1. Design, synthesis, and lead identification

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 3, 2008, Pages 1135-1139

  Yang, Shyh Ming ^a   Scannevin, Robert H ^a   Wang, Bingbing ^a   Burke, Sharon L ^a   Wilson, Lawrence J ^a   Karnachi, Prabha ^a   Rhodes, Kenneth J ^a   Lagu, Bharat ^a   Murray, William V ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Gelatinase; Hydroxamate; Matrix metalloproteinase; MMP inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; CGS 27023A; GELATINASE A; GELATINASE B; GELATINASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; INTERSTITIAL COLLAGENASE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG DESIGN; GELATINASES; HUMANS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICROSOMES, LIVER; MOLECULAR STRUCTURE; PYRAZINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 38749133358     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.11.119     Document Type: Article

References (22)

1. Recent reviews, see:. Fingleton B. Curr. Pharm. Des. 13 (2007) 333
2. Fingleton B. Exp. Opin. Ther. Targets 7 (2003) 385
3. Vihinen P., Ala-aho R., and Kähäri V.-M. Curr. Cancer Drug Targets 5 (2005) 203
4. George S.J. Exp. Opin. Invest. Drugs 9 (2000) 993
5. Yong V.W. Exp. Opin. Invest. Drugs 8 (1999) 255
6. Yong V.W., Power C., Forsyth P., and Edwards D.R. Nat. Rev. Neurosci. 2 (2001) 502
7. Recent reviews, see:. Whittaker M., Floyd C.D., Brown P., and Gearing A.J.H. Chem. Rev. 99 (1999) 2735
8. Matter H., and Schudok M. Curr. Opin. Drug Discov. Dev. 7 (2004) 513
9. Fisher J.F., and Mobashery S. Cancer Metastasis Rev. 25 (2006) 115
10. Sang Q.-X.A., Jin Y., Newcomer R.G., Monroe S.C., Fang X., Hurst D.R., Lee S., Cao Q., and Schwartz M.A. Curr. Top. Med. Chem. 6 (2006) 289
11. Supuran C.T., Casini A., and Scozzafava A. Med. Res. Rev. 23 (2003) 535
12. It has been addressed that the metabolism of hydroxamic acid might be reduced by sterically hindering this functionality, see:. Reiter L.A., Robinson R.P., McClure K.F., Jones C.S., Reese M.R., Mitchell P.G., Otterness I.G., Bliven M.L., Liras J., Cortina S.R., Donahue K.M., Eskra J.D., Griffiths R.J., Lame M.E., Lopez-Anaya A., Martinelli G.J., McGahee S.M., Yocum S.A., Lopresti-Morrow L.L., Tobiassen L.M., and Vaughn-Bowser M.L. Bioorg. Med. Chem. Lett. 14 (2004) 3389
13. Noe M.C., Natarajan V., Snow S.L., Mitchell P.G., Lopresti-Morrow L., Reeves L.M., Yocum S.A., Carty T.J., Barberia J.A., Sweeney F.J., Liras J.L., Vaughn M., Hardink J.R., Hawkins J.M., and Tokar C. Bioorg. Med. Chem. Lett. 15 (2005) 2808
14. MacPherson L.J., Bayburt E.K., Capparelli M.P., Carroll B.J., Goldstein R., Justice M.R., Zhu L., Hu S., Melton R.A., Fryer L., Goldberg R.L., Doughty J.R., Spirito S., Blancuzzi V., Wilson D., O'Byrne E.M., Ganu V., and Parker D.T. J. Med. Chem. 40 (1997) 2525 (further clinical trials with CGS-27023A have been cancelled due to lack of clear efficacy in Phase II trials, and to side effects)
15. In the design of amide- or sulfonamide-based MMP inhibitors, typically, the biaryl ether portion (P1′) was attached to the sulfonyl group instead of on the nitrogen atom. Few exceptions, see:. Cherney R.J., Mo R., Meyer D.T., Hardman K.D., Liu R.-Q., Covington M.B., Qian M., Wasserman Z.R., Christ D.D., Trzaskos J.M., Newton R.C., and Decicco C.P. J. Med. Chem. 47 (2004) 2981
16. Kim S.-H., Pudzianowski A.T., Leavitt K.J., Barbosa J., McDonnell P.A., Metzler W.J., Rankin B.M., Liu R., Vaccaro W., and Pitts W. Bioorg. Med. Chem. Lett. 15 (2005) 1101
17. Yang S.-M., and Murray W.V. Tetrahedron Lett. (2008) 10.1016/j.tetlet.2007.11.184
18. Albanese D., Landini D., Lupi V., and Penso M. Ind. Eng. Chem. Res. 42 (2003) 680 (and references cited therein)
19. The condition was adopted from Ref. 5.
20. 50s were determined in triplicate for each compound using 16-point concentration-response curves and fit using nonlinear regression analysis in Graphpad Prism 4.0 (Graphpad Software, San Diego, CA).
21. Peterson J.T. Heart Failure Rev. 9 (2004) 63
22. Brown P.D. APMIS 107 (1999) 174